Fascin as a Prognostic Indicator in Lung Cancer
Author Information
Author(s): Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, Viale G
Primary Institution: University of Milan School of Medicine
Hypothesis
Does fascin immunoreactivity correlate with prognosis in stage I nonsmall cell lung cancer (NSCLC)?
Conclusion
Fascin is overexpressed in most NSCLC and serves as an independent prognostic indicator of reduced survival.
Supporting Evidence
- Fascin was detected in 89% of NSCLC cases.
- Patients with high fascin levels had shorter overall survival.
- Fascin expression correlates with tumor grade and proliferative activity.
Takeaway
Fascin is a protein that helps cancer cells move and grow. In lung cancer, if there's a lot of fascin, it usually means the cancer is more aggressive and harder to treat.
Methodology
The study analyzed fascin immunoreactivity in 220 patients with stage I NSCLC using immunocytochemistry and statistical survival analysis.
Potential Biases
Potential observer bias in evaluating immunoreactivity.
Limitations
The study did not include complete smoking history data for all patients.
Participant Demographics
199 males and 21 females, aged 35 to 80 years.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website